Drug candidates

#Collaboration #Drug candidates #Drug discovery

Drug discovery collaboration tackles metabolic diseases

Evotec has entered into a drug discovery collaboration with Eli Lilly and Company (Lilly) in the field of metabolic diseases with a focus on kidney diseases and diabetes.  The collaboration  The collaboration leverages Evotec’s metabolic disease experience, as well as its kidney disease patient database,… Read More

#News

#Collaboration #Drug candidates #Drug development #Drug discovery

Call for application: AI for antibody design 

German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges.  The chosen AION Labs startup… Read More

#News

#Alzheimer's #Clinical trials #Drug candidates #Drug discovery

First patients dosed in Phase I study for Alzheimer’s

AlzeCure Pharma has dosed the first patient in the company’s next clinical Phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer’s disease. ”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase… Read More

#News #Trending News

#AI #AI / data analytics / healthtech / informatics #Drug candidates #Drug design #Drug discovery #Research

AI accelerates discovery of small molecule drug candidates

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in… Read More

#News

#Biotherapeutics #Drug candidates #Drug development #Therapeutics

Eli Lilly and MiNA Therapeutics saRNA research collaboration

Eli Lilly and Company and MiNA Therapeutics have created a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. MiNA will utilise its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key… Read More

#News

#Biopharmaceutical #Drug candidates #Drug development #Drug discovery #Metabolomics

Using the power of plants in drug discovery

Viswa Colluru, PhD, founder and CEO of Enveda Biosciences talks to Lu Rahman about the company’s chemical search engine and its work harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges.  LR: Describe what Enveda does and some of its current work / initiatives. VC: Enveda… Read More

#Exclusive Content #News #Opinion

#Drug candidates #Drug delivery #Drug development #Drug discovery #Gene therapy

Ilya’s ILP100 gene therapy speeds up healing by six days on average

Clinical stage gene therapy company, Ilya Pharma, has released further results from the first in human (FIH) trial of ILP100 for treating difficult and chronic wounds. ILP100 represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the wound site. After delivery, ILP100 enhances the healing properties of immune cells in the… Read More

#News

#Biomarkers #Drug candidates #Drug development #Drug discovery #Hits #Target validation

Evotec and Related Sciences form drug discovery and development partnership

Evotec has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Related Sciences will jointly discover and develop a range of therapeutic approaches for clearly defined patient populations… Read More

#Editor's Choice #News

#Clinical trials #Drug candidates #Drug targets #Life sciences #Therapeutics

One Nucleus announces life science award shortlist

One Nucleus has revealed the finalists of its annual BioNewsRound Award, recognising life science companies with exciting developments. The finalists will pitch in the lead up to Genesis 2020 during which the winner will be announced. Companies and research organisations were nominated for their most important updates from the last… Read More

#News

#Autoimmune disease #Drug candidates #Drug discovery

Beetroot peptide potential drug candidate for neurodegenerative and inflammatory diseases

In a recent study, a research group led by Christian Gruber at MedUni Vienna’s Institute of Pharmacology isolated a peptide (small protein molecule) from beetroot. The peptide is able to inhibit a particular enzyme that is responsible for the breakdown of messenger molecules in the body. Due to its particularly… Read More

#Editor's Choice #News

#Drug candidates #Live bio therapeutics #Pharmaceutical

4D pharma merger with Longevity to gain NASDAQ listing

4D pharma, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition a NASDAQ-listed Special Purpose Acquisition Company (SPAC), have announced a proposed merger. The deal is worth up to $37.6 million to 4D pharma. Read More

#News

#Drug candidates #Drug discovery

BioIVT kit aids liver toxicity and inflammation studies for drug discovery research

BioIVT has launched the HEPATOMUNE kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury. Hepatomune cultures are composed of hepatocytes, stromal cells and Kupffer cells in a tri-culture, mimicking the physiological microenvironment of the liver, and providing an optimal model for studying cytokines and cytokine… Read More

#News

#AI / data analytics / healthtech / informatics #Covid-19 #Drug candidates #Drug development #MS #Therapeutics

New for old: the value behind drug repurposing  

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug… Read More

#Covid-19 #Exclusive Content #Trends & Analysis